Biotech Values

[Pre_Clinical]

Regarding ALTUS's hGH program....

My concern is both safety and efficacy, but I am willing to give their team the benefit of the doubt on this particular program. The fact that they were able to partner with DNA speaks volumes, IMO. Genentech's dd process for deals is really tough- I know from personal experience. DNA invested 15MM in the company and also gave up 15 MM in cash. That's good money and an excellent validation of the company's technology platform. However, Im still much more high on the pancreatic insufficency indication. That's a great first shot on goal for this company.